Skip to main content

Drug profiling to target commercial motor market

A new service, designed specifically to cut commercial motor insurance premiums by providing alcohol and drugs profiling of drivers, has been launched by Trimega Laboratories.

Trimega’s Fleet Profile, carried out using hair samples, could reduce premiums by confirming that commercial drivers are not alcohol or drug abusers. The hair samples, which are collected on-site or at a London walk-in clinic, provide an accurate historical record of any alcohol or drugs dependency over a three to twelve month period.

Since hair growth is fed by the bloodstream, the ingestion of drugs or excess alcohol in the blood is revealed by analysing chemical markers absorbed by the hair

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@insuranceage.co.uk or view our subscription options here: https://subscriptions.insuranceage.co.uk/subscribe

You are currently unable to copy this content. Please contact info@insuranceage.co.uk to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Age? View our subscription options

Why The Mills Review is the AI starting pistol for brokers

Most coverage of The Mills Review, published on 6 July, has focused on what it does not do. There is no new AI rulebook, no new obligations and nothing specific to implement. But that somewhat misses the point, writes Robin Knowles, compliance consultant at UKGI.

Most read articles loading...

You need to sign in to use this feature. If you don’t have an Insurance Age account, please register now.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: